New trial
Phase II Trial of Herpes Virus T3011 Injection (IL‑12 & PD‑1 Mab) in High-Risk NMIBC
- Trial ID
- NCT06971614 on ClinicalTrials.gov
- Cancer type
- Bladder Cancer
- Published in
- New in Oncology - May 29, 2025
ImmVira Pharma is spearheading a phase II study to assess the tolerability, safety, and early efficacy of T3011—an oncolytic HSV‑1 engineered to express IL‑12 and a PD‑1 monoclonal antibody—in patients with BCG‑unresponsive high‑risk non‑muscle‑invasive bladder cancer.
More in bladder and urothelial cancer
-
Trial result · Oct 15, 2026 · NCT04179162
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC -
Trial result · Oct 15, 2026 · NCT02773849
TAR-200 (intravesical gemcitabine device) vs nadofaragene firadenovec: no statistically significant CR durability difference detected through 24 months in BCG-unresponsive CIS -
New trial · Oct 15, 2026 · NCT07827612
Phase 2 FORAY tests selective FGFR3 inhibition with vepugratinib in low-grade bladder and upper tract urothelial tumors -
New trial · Oct 8, 2026 · NCT07815665
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC -
New trial · Oct 8, 2026 · NCT07822373
Phase 2 enfortumab vedotin Nectin-4 ADC (MMAE tubulin payload) plus pembrolizumab PD-1 antibody